## User

This is the beginning of an individual meeting with Principal Investigator to discuss your research project.

Here are summaries of the previous meetings:

[begin summary 1]

To address the agenda for optimizing the nanobody design process using ESM, AlphaFold-Multimer, and Rosetta, here is a detailed plan that aligns with the constraints and goals of the project:

1. **Order of Operations in Each Iteration:**
   - **Step 1:** Use ESM to evaluate all potential mutations to the nanobody. This step is computationally efficient and will allow us to rapidly screen for promising mutations.
   - **Step 2:** Select a subset of the highest-scoring mutations from the ESM evaluation for further analysis.
   - **Step 3:** Use AlphaFold-Multimer to predict the nanobody-antigen structure for each selected mutation. This step considers structural accuracy and binding prediction.
   - **Step 4:** Use Rosetta to refine the structure predicted by AlphaFold-Multimer and calculate the binding energy for each mutation. This step provides a detailed assessment of binding affinity changes.

2. **Number of Mutations Evaluated in Each Iteration:**
   - Start with evaluating all potential mutations using ESM. After obtaining ESM scores, select the top 20 mutations for evaluation with AlphaFold-Multimer and Rosetta to manage computational resources efficiently.

3. **Formula to Weigh Scores:**
   - Develop a composite score (CS) for each mutation using the formula:
     \[
     \text{CS} = w_1 \cdot \text{ESM Score} + w_2 \cdot \text{(AlphaFold-Multimer Interface pLDDT)} - w_3 \cdot |\text{Rosetta Binding Energy}|
     \]
   - Choose weights \(w_1, w_2, w_3\) based on the relative importance of prediction accuracy (AlphaFold-Multimer), computational efficiency (ESM), and refinement precision (Rosetta). For instance, initial weights could be \(w_1 = 0.2\), \(w_2 = 0.4\), \(w_3 = 0.4\).

4. **Number of Top-Ranked Mutations to Keep:**
   - Keep the top 5 mutations based on the composite score for the next iteration. This allows for a focused exploration of promising mutations while maintaining diversity.

5. **Decision on Number of Iterations:**
   - Continue iterations until the improvement in the composite score across mutations plateaus or starts to decrease. Set an upper limit of 3-5 iterations to balance computational time with potential gains in binding affinity.

6. **Selection of the Final Set of 24 Modified Nanobodies:**
   - **Step 1:** Compile all mutations evaluated in each iteration.
   - **Step 2:** Rank all mutations based on their final composite score.
   - **Step 3:** Select the top 24 unique mutations with the highest composite scores for experimental validation, ensuring coverage of a range of structural and sequence diversity.
   - **Step 4:** Confirm that the selected nanobodies span a broad spectrum of mutations affecting different regions of the nanobody to maximize the likelihood of broad-spectrum activity against various spike protein variants.

By following this plan, we can efficiently explore the mutation landscape and identify nanobody candidates with optimal binding characteristics for experimental validation.

[end summary 1]

[begin summary 2]

To address the agenda for the meeting, here's a structured plan for utilizing the ESM, AlphaFold-Multimer, and Rosetta tools within the constraints provided:

### 1. Order of Operations for Evaluating Mutations

**Step 1: ESM Scoring**
- Evaluate all potential mutations of the starting nanobody using ESM. This step is crucial for a rapid first pass to filter mutations with promising binding potentials.

**Step 2: AlphaFold-Multimer Prediction**
- Select the top mutations from the ESM scoring (see the number in the next section) and predict their structures using AlphaFold-Multimer. This will provide detailed structural predictions necessary for further analysis.

**Step 3: Rosetta Scoring**
- Use the structures predicted by AlphaFold-Multimer and assess the binding energy of each mutation using Rosetta. This step refines the selection by evaluating the likely binding efficiency.

### 2. Number of Mutations Evaluated

- **ESM:** Evaluate all potential single-point mutations for the nanobody in parallel. This is feasible given its rapid evaluation time.
- **AlphaFold-Multimer:** Select the top 10 mutations based on ESM scores for further evaluation, given the longer computation time required.
- **Rosetta:** Evaluate these same 10 mutations since they depend on the AlphaFold-Multimer predictions.

### 3. Formula for Weighing Scores

To rank the nanobody mutations after each iteration, use a weighted scoring formula that balances the strengths and weaknesses of each tool:

\[ \text{Score} = w_1 \times \text{normalized ESM score} + w_2 \times \text{normalized AlphaFold-Multimer pLDDT} + w_3 \times \text{normalized Rosetta binding energy} \]

- Suggested weights: \( w_1 = 0.3 \), \( w_2 = 0.3 \), \( w_3 = 0.4 \) (adjust based on pilot results)

### 4. Number of Top-Ranked Mutations Kept

- Keep the top 3 mutations from each iteration for the next round. These mutations will be used to generate further derivative mutations in the subsequent iteration.

### 5. Deciding the Number of Iterations

- Run a sufficient number of iterations until a saturation point is reached, where additional iterations do not significantly improve the top scores. Initial target: 5-7 iterations, adjusted based on observed convergence of scores.

### 6. Final Selection of 24 Modified Nanobodies

**Step-by-Step Selection Process:**

1. **Compile Results:** Gather all evaluated mutations and their scores across all iterations.
2. **Rank Mutations:** Sort all mutations based on their weighted scores.
3. **Diversity Check:** Ensure coverage of diverse mutations by considering both sequence diversity and structural diversity (assessed by predicted structures).
4. **Select Top 24:** Choose the top 24 mutations, ensuring a mix of high scores and diversity to maximize potential for broad-spectrum efficacy.
5. **Review with Team:** Conduct a final review with the team to assess any additional insights or considerations before experimental validation.

This plan ensures efficient use of computational resources while maximizing the likelihood of identifying high-affinity nanobodies against the SARS-CoV-2 spike protein variant.

[end summary 2]

[begin summary 3]

To address the agenda questions, we will design an iterative process for optimizing nanobodies using ESM, AlphaFold-Multimer, and Rosetta. Here’s how we plan to proceed:

1. **Order of Operations in Each Iteration:**

   - **Step 1:** Use ESM to score all potential single-point mutations of the current nanobody. Given the speed of this tool, ESM will provide an initial screening of mutations based on log-likelihood ratios.
   - **Step 2:** Select a subset of the top mutations based on ESM scores to proceed with structure prediction.
   - **Step 3:** Use AlphaFold-Multimer on the top-ranked mutations from ESM to predict the structural impact and calculate the interface pLDDT confidence scores.
   - **Step 4:** Use Rosetta to refine and evaluate the binding energies of AlphaFold-Multimer predicted structures.

2. **Number of Mutations Evaluated in Each Iteration:**

   - **ESM:** Evaluate all possible mutations (since it is computationally inexpensive and quick).
   - **AlphaFold-Multimer and Rosetta:** Given the time constraints, evaluate approximately 10 mutations per iteration, balancing between computational feasibility and diversity of mutations.

3. **Weighing and Ranking Mutations:**

   - Create a composite score for each mutation using a weighted formula that balances the results from each tool:
     \[
     \text{Composite Score} = w_1 \times \text{(ESM Score)} + w_2 \times \text{(AlphaFold-Multimer Score)} - w_3 \times \text{(Rosetta Score)}
     \]
   - Weights (\(w_1, w_2, w_3\)) can be adjusted based on their relative importance. An initial choice could be \(w_1 = 0.3\), \(w_2 = 0.4\), \(w_3 = 0.3\) to give more weight to structural and binding predictions.

4. **Number of Top-Ranked Mutations Kept for Next Round:**

   - Keep the top 3 mutations from each iteration to introduce diversity while maintaining efficiency in the iterative process.

5. **Deciding Number of Iterations:**

   - Plan for approximately 4 iterations. This allows for a thorough exploration of the mutation space within the computational time constraints, while progressively improving the nanobody design.

6. **Selection of Final 24 Modified Nanobodies:**

   - **Step 1:** Compile all mutations retained from each iteration.
   - **Step 2:** Calculate and rank the composite scores for all these mutations.
   - **Step 3:** Select the top 24 unique mutations with the highest composite scores for experimental validation. Ensure diversity by checking for structural novelty and different binding sites if applicable.
   - **Step 4:** Consult with the team to review the final selection to ensure alignment with experimental feasibility and potential for broad variant coverage.

This strategy should efficiently guide the nanobody optimization process within the given constraints and maximize the likelihood of achieving nanobodies with strong binding across variants.

[end summary 3]

[begin summary 4]

To address the agenda questions effectively, we need to plan the iterative design process to maximize efficiency and ensure the best possible outcomes in terms of nanobody binding improvement while adhering to the time constraints. Here's a detailed response to each of the agenda questions:

1. **Order of Operations for Evaluating Mutations:**

   In each iteration, the order of operations for evaluating mutations should be:
   - **Step 1:** Use ESM to quickly evaluate all potential mutations to the nanobody. This will allow us to perform an initial, rapid screening to identify promising mutations.
   - **Step 2:** For the top mutations identified by ESM, use AlphaFold-Multimer to predict the nanobody-antigen complex structure and evaluate the mutation's effect on the interface confidence score.
   - **Step 3:** Finally, use Rosetta to perform detailed binding energy calculations on the structures predicted by AlphaFold-Multimer.

2. **Number of Mutations to Evaluate:**

   In each iteration, we will start with evaluating all potential mutations using ESM, since it takes only 5 minutes for this step. However, due to time constraints with AlphaFold-Multimer, we should limit the number of top mutations from the ESM evaluation to a manageable number, say **20 mutations**, to pass on for further evaluation with AlphaFold-Multimer and subsequently with Rosetta.

3. **Weighing the Scores to Rank Mutations:**

   To rank the mutations at the end of each iteration, we will use a weighted formula incorporating the scores from ESM, AlphaFold-Multimer, and Rosetta. A potential formula could be:

   \[
   \text{Composite Score} = w_1 \times \text{ESM Score} + w_2 \times (\text{AlphaFold-Multimer Score}) - w_3 \times (\text{Rosetta Score})
   \]

   Where \(w_1\), \(w_2\), and \(w_3\) are weights that should be determined based on the relative importance and reliability of each scoring metric. For example, initial weights might be set to \(w_1 = 1\), \(w_2 = 0.5\), \(w_3 = 0.2\), reflecting the rapid screening capability of ESM and the structural insights provided by AlphaFold and Rosetta.

4. **Top-Ranked Mutations to Keep:**

   At the end of each iteration, we will keep the **top 5 mutations** based on the composite score to carry forward to the next round. This number ensures diversity while maintaining focus on the most promising candidates.

5. **Deciding Number of Iterations:**

   The number of iterations will depend on the convergence of the composite scores. We can aim for approximately 3-5 iterations, monitoring the improvement in scores and assessing if improvements plateau.

6. **Selecting Final Set of 24 Modified Nanobodies:**

   - **Step 1:** Compile all mutations evaluated across iterations with their composite scores.
   - **Step 2:** Rank all the mutations globally based on their composite scores.
   - **Step 3:** Select the top 24 mutations with the highest composite scores for experimental validation, ensuring diversity by not choosing closely related mutations within the list.

This structured approach should facilitate the design of effective nanobody variants against the SARS-CoV-2 spike protein, leveraging computational resources efficiently while adhering to the project timeline.

[end summary 4]

[begin summary 5]

To effectively approach this project, here is a detailed plan addressing each of the agenda questions:

1. **Order of Operations for Evaluating Mutations:**
   - **Step 1: ESM Evaluation** - Begin each iteration by using ESM to quickly evaluate all potential mutations. This will allow us to narrow down the pool of mutations to those most likely to enhance binding affinity, based on log-likelihood ratios.
   - **Step 2: AlphaFold-Multimer Prediction** - For the top mutations identified by ESM, run AlphaFold-Multimer to predict the structure of the nanobody-antigen complex, focusing on interface pLDDT scores.
   - **Step 3: Rosetta Scoring** - Use Rosetta to evaluate the binding energy of the predicted structures from AlphaFold-Multimer, providing a detailed assessment of binding affinity.

2. **Number of Mutations to Evaluate:**
   - **ESM Evaluation:** All potential mutations (since this is computationally inexpensive).
   - **AlphaFold-Multimer and Rosetta Evaluation:** Select the top 10 mutations as identified by the ESM scores for further analysis. This balances computational cost with the need to explore a diverse mutation space.

3. **Scoring Formula to Rank Mutations:**
   - Combine scores from the three tools using a weighted formula. For simplicity and given the ranges, let's propose: 
     \[
     \text{Combined Score} = \alpha \cdot \text{ESM Score} + \beta \cdot \text{AlphaFold-Multimer Score} - \gamma \cdot \text{Rosetta Score}
     \]
   - Suggested weights could be based on their relative impact and reliability: \(\alpha = 1\), \(\beta = 2\), \(\gamma = 0.5\). These weights can be adjusted as more data is collected and analyzed.

4. **Number of Top-Ranked Mutations to Keep:**
   - Select the top 5 mutations based on the combined score from each iteration to carry forward to the next round. This ensures that promising mutations are iteratively improved upon.

5. **Deciding Number of Iterations:**
   - Plan for approximately 5-7 iterations within the time constraint. This allows for a broad exploration of the mutation space while iteratively refining the designs based on feedback from the predictive models.

6. **Selecting the Final Set of 24 Modified Nanobodies:**
   - **Step 1:** Compile a list of all mutations from all iterations.
   - **Step 2:** Rank these mutations based on their final iteration's combined score.
   - **Step 3:** Select the top 24 unique mutations that maximize diversity in the mutation space while maintaining high scores.
   - **Step 4:** Ensure representation of mutations from various iterations to capture any potentially synergistic effects of earlier mutations.
   - **Step 5:** Prepare these 24 nanobody designs for experimental validation.

This approach ensures a comprehensive, data-driven exploration of nanobody modifications to optimize binding to the newest variant of the SARS-CoV-2 spike protein, while efficiently managing computational resources and project timelines.

[end summary 5]

Here is the agenda for the meeting:

Please read the summaries of multiple separate meetings about the same agenda. Based on the summaries, provide a single answer that merges the best components of each individual answer. Please use the same format as the individual answers. Additionally, please explain what components of your answer came from each individual answer and why you chose to include them in your answer.

As a reference, here is the agenda from those meetings, which must be addressed here as well:

You are working on a research project to use machine learning to develop antibodies or nanobodies for the newest variant of the SARS-CoV-2 spike protein that also, ideally, have activity against other circulating minor variants and past variants. Your team previous decided to modify existing nanobodies to improve their binding to the newest variant of the SARS-CoV-2 spike protein. Your team has built three components of a nanobody design pipeline: ESM, AlphaFold-Multimer, and Rosetta. Each of these three tools can be used to score a nanobody mutation based on how the mutation affects binding to an antigen. Your goal is to start with an existing nanobody and iteratively add mutations to it to improve its binding to the newest variant of the SARS-CoV-2 spike protein, resulting in 24 modified nanobodies with one or more mutations. Please determine how to use ESM, AlphaFold-Multimer, and Rosetta in this iterative design process. An important constraint is that ESM can evaluate all potential mutations to a nanobody in 5 minutes while AlphaFold-Multimer takes 30 minutes per mutation and Rosetta takes five minutes per mutation. The whole iterative process should take no more than a few days to complete. Note that AlphaFold-Multimer must be run before Rosetta on each mutation since Rosetta requires the nanobody-antigen structure predicted by AlphaFold-Multimer. Additionally, note that ESM log-likelihood ratios are generally in the range of 5-10 (higher is better), AlphaFold-Multimer interface pLDDT confidence scores are generally in the range of 60-80 (higher is better), and Rosetta binding energy scores are generally in the range of -20 to -40 (lower is better).

As a reference, here are the agenda questions from those meetings, which must be answered here as well:

1. In each iteration, what is the order of operations for evaluating mutations with ESM, AlphaFold-Multimer, and Rosetta?

2. In each iteration, how many mutations (give a single number) will you evaluate with ESM, AlphaFold-Multimer, and Rosetta?

3. At the end of each iteration, how will you weigh the ESM, AlphaFold-Multimer, and/or Rosetta scores (give a formula) to rank the nanobody mutations?

4. At the end of each iteration, how many of the top-ranked mutations (give a single number) will you keep for the next round?

5. How will you decide how many iterations of mutations to run?

6. After all of the iterations are complete, how exactly (step-by-step) will you select the final set of 24 modified nanobodies from across the iterations for experimental validation?



Principal Investigator, please provide your response to the agenda.

## Principal Investigator

To address the agenda questions effectively, I have synthesized the best components from each summary to create a comprehensive plan for the iterative design process of optimizing nanobodies using ESM, AlphaFold-Multimer, and Rosetta. Here is the detailed plan:

### 1. Order of Operations for Evaluating Mutations

**Step 1: ESM Evaluation**
- Use ESM to evaluate all potential single-point mutations of the starting nanobody. This step is computationally efficient and provides an initial screening based on log-likelihood ratios.

**Step 2: AlphaFold-Multimer Prediction**
- Select the top mutations from the ESM evaluation for structure prediction using AlphaFold-Multimer. This step provides detailed structural predictions necessary for further analysis.

**Step 3: Rosetta Scoring**
- Use Rosetta to refine the structures predicted by AlphaFold-Multimer and calculate the binding energy for each mutation. This step assesses the likely binding efficiency.

**Rationale:** This order of operations is consistently recommended across all summaries, emphasizing the logical progression from rapid screening (ESM) to detailed structural and binding analysis (AlphaFold-Multimer and Rosetta).

### 2. Number of Mutations Evaluated

- **ESM:** Evaluate all potential mutations since it is computationally inexpensive.
- **AlphaFold-Multimer and Rosetta:** Evaluate 10 mutations per iteration. This number balances computational feasibility with the need to explore a diverse mutation space.

**Rationale:** The choice of evaluating 10 mutations with AlphaFold-Multimer and Rosetta is a compromise between computational constraints and the need for diversity, as suggested in summaries 2, 3, and 5.

### 3. Formula for Weighing Scores

Use a composite score to rank the mutations:

\[
\text{Composite Score} = w_1 \times \text{normalized ESM Score} + w_2 \times \text{normalized AlphaFold-Multimer pLDDT} - w_3 \times \text{normalized Rosetta Binding Energy}
\]

- Suggested weights: \(w_1 = 0.3\), \(w_2 = 0.4\), \(w_3 = 0.3\).

**Rationale:** This formula and weighting scheme are derived from summaries 2 and 3, which emphasize balancing the strengths of each tool while considering their computational costs and predictive reliability.

### 4. Number of Top-Ranked Mutations Kept

- Keep the top 3 mutations from each iteration for the next round.

**Rationale:** Keeping the top 3 mutations ensures diversity while maintaining focus on the most promising candidates, as suggested in summaries 2 and 3.

### 5. Deciding Number of Iterations

- Plan for approximately 4-5 iterations, monitoring the convergence of composite scores to determine when improvements plateau.

**Rationale:** This approach balances thorough exploration with computational efficiency, as recommended in summaries 3 and 4.

### 6. Selecting the Final Set of 24 Modified Nanobodies

**Step-by-Step Selection Process:**

1. **Compile Results:** Gather all evaluated mutations and their scores across all iterations.
2. **Rank Mutations:** Sort all mutations based on their final composite scores.
3. **Diversity Check:** Ensure coverage of diverse mutations by considering both sequence diversity and structural diversity.
4. **Select Top 24:** Choose the top 24 mutations, ensuring a mix of high scores and diversity to maximize potential for broad-spectrum efficacy.
5. **Review with Team:** Conduct a final review with the team to assess any additional insights or considerations before experimental validation.

**Rationale:** This comprehensive selection process, incorporating steps from summaries 2, 4, and 5, ensures a balanced and diverse set of nanobody candidates for experimental validation.

By integrating these components, we can efficiently explore the mutation landscape and identify nanobody candidates with optimal binding characteristics for experimental validation.

